“Fast Track designation marks an important step in expediting the development of buloxibutid for the treatment of IPF,” says Ahmed Mousa, Chief Executive Officer of Vicore. “This milestone reflects the potential of buloxibutid to offer significant improvement over existing treatments and to make a meaningful impact on IPF patients’ lives. We look forward to working closely with the FDA to support the development of buloxibutid and to make it available to those suffering from this devastating disease as quickly as possible.”

Related article

Vicore Pharma is the winner of SwedenBIO Award

Vicore Pharma is praised for being at the forefront of addressing unmet medical needs in rare diseases and for securing one of Sweden’s largest biotech raises in 2024.

Buloxibutid

Buloxibutid is a first-in-class angiotensin II type 2 (AT2) receptor agonist that activates an upstream mechanism to drive alveolar repair, resolve fibrosis, and promote pulmonary vascular function.

The Phase 2b ASPIRE trial to assess the safety and efficacy of buloxibutid in patients suffering from IPF is now enrolling.